Multimodal Management of Retroperitoneal Lymph Node Metastases in Colorectal Cancer: A Single-Center Retrospective Analysis.

IF 3.5 2区 医学 Q2 ONCOLOGY
Arthur Houbiers, Remy Barbe, Jerome Durand-Labrunie, Valerie Boige, Cristina Smolenschi, Antoine Hollebecque, Yves Menu, Marine Valery, Michel Ducreux, Alice Boileve, Elena Fernandez de Sevilla, Leonor Benhaim, Peggy Dartigues, Isabelle Sourrouille, Mohamed Amine Bani, Maximiliano Gelli
{"title":"Multimodal Management of Retroperitoneal Lymph Node Metastases in Colorectal Cancer: A Single-Center Retrospective Analysis.","authors":"Arthur Houbiers, Remy Barbe, Jerome Durand-Labrunie, Valerie Boige, Cristina Smolenschi, Antoine Hollebecque, Yves Menu, Marine Valery, Michel Ducreux, Alice Boileve, Elena Fernandez de Sevilla, Leonor Benhaim, Peggy Dartigues, Isabelle Sourrouille, Mohamed Amine Bani, Maximiliano Gelli","doi":"10.1245/s10434-025-18106-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Retroperitoneal lymph node metastases (RLNMs) of colorectal cancer (CRC) have a low incidence, and the optimal treatment strategy remains unclear due to limited evidence. This study aimed to analyze morbidity and long-term oncologic outcomes associated with different multimodal approaches including systemic chemotherapy, surgery with or without preoperative radiotherapy.</p><p><strong>Methods: </strong>This retrospective, single-center study included consecutive patients treated from 2000 to 2023 for sub-renal RLNM from CRC. After induction chemotherapy, the patients were divided into two groups: those receiving radio(chemo)therapy (RCT) followed by surgery (RCT-surgery group; n = 30) and those undergoing upfront surgery (surgery-alone group; n = 24). The study analyzed treatment methods, perioperative data, morbidity, mortality, overall survival (OS), and recurrence-free survival (RFS).</p><p><strong>Results: </strong>The study included 54 patients (32 males, 22 females, age 51 years). Presentation of RLNM was synchronous in 48.1% (n = 25) of the patients, and 25.9% (n = 14) of the patients had previously treated extra-nodal metastases. Standardized retroperitoneal nodal dissection (RND) was performed for 40 (90.7%) patients. Operative time, blood loss, severe postoperative morbidity, and hospital length of stay were similar between the RCT-surgery and surgery-alone groups. Preoperative RCT was associated with a higher rate of complete response (18.2% vs 0%; p = 0.018). The median RFS was 13.1 months for the RCT-surgery group and 8.6 months for the surgery-alone group (p = 0.153). The median OS was 73.9 months for the surgery-alone group and not reached in the RCT-surgery group (p = 0.909).</p><p><strong>Conclusion: </strong>A multimodal curative strategy combining nodal dissection after systemic chemotherapy with or without preoperative RCT for RLNM from CRC is feasible, demonstrating low morbidity and promising oncologic outcomes in advanced metastatic disease.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-025-18106-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Retroperitoneal lymph node metastases (RLNMs) of colorectal cancer (CRC) have a low incidence, and the optimal treatment strategy remains unclear due to limited evidence. This study aimed to analyze morbidity and long-term oncologic outcomes associated with different multimodal approaches including systemic chemotherapy, surgery with or without preoperative radiotherapy.

Methods: This retrospective, single-center study included consecutive patients treated from 2000 to 2023 for sub-renal RLNM from CRC. After induction chemotherapy, the patients were divided into two groups: those receiving radio(chemo)therapy (RCT) followed by surgery (RCT-surgery group; n = 30) and those undergoing upfront surgery (surgery-alone group; n = 24). The study analyzed treatment methods, perioperative data, morbidity, mortality, overall survival (OS), and recurrence-free survival (RFS).

Results: The study included 54 patients (32 males, 22 females, age 51 years). Presentation of RLNM was synchronous in 48.1% (n = 25) of the patients, and 25.9% (n = 14) of the patients had previously treated extra-nodal metastases. Standardized retroperitoneal nodal dissection (RND) was performed for 40 (90.7%) patients. Operative time, blood loss, severe postoperative morbidity, and hospital length of stay were similar between the RCT-surgery and surgery-alone groups. Preoperative RCT was associated with a higher rate of complete response (18.2% vs 0%; p = 0.018). The median RFS was 13.1 months for the RCT-surgery group and 8.6 months for the surgery-alone group (p = 0.153). The median OS was 73.9 months for the surgery-alone group and not reached in the RCT-surgery group (p = 0.909).

Conclusion: A multimodal curative strategy combining nodal dissection after systemic chemotherapy with or without preoperative RCT for RLNM from CRC is feasible, demonstrating low morbidity and promising oncologic outcomes in advanced metastatic disease.

结直肠癌腹膜后淋巴结转移的多模式治疗:单中心回顾性分析。
背景:结直肠癌(CRC)腹膜后淋巴结转移(RLNMs)发病率低,由于证据有限,最佳治疗策略尚不清楚。本研究旨在分析不同多模式治疗方法的发病率和长期肿瘤预后,包括全身化疗、手术加术前或不加术前放疗。方法:这项回顾性、单中心研究纳入了2000年至2023年连续接受结直肠癌亚肾RLNM治疗的患者。诱导化疗后,将患者分为放疗后手术组(RCT-手术组,n = 30)和术前手术组(单纯手术组,n = 24)。该研究分析了治疗方法、围手术期数据、发病率、死亡率、总生存期(OS)和无复发生存期(RFS)。结果:共纳入54例患者,其中男32例,女22例,年龄51岁。在48.1% (n = 25)的患者中,RLNM的出现是同步的,25.9% (n = 14)的患者之前接受过淋巴结外转移治疗。40例(90.7%)患者行标准化腹膜后淋巴结清扫(RND)。手术时间、出血量、术后严重并发症和住院时间在随机对照手术组和单独手术组之间相似。术前RCT与更高的完全缓解率相关(18.2% vs 0%; p = 0.018)。rct -手术组的中位RFS为13.1个月,单纯手术组的中位RFS为8.6个月(p = 0.153)。单纯手术组的中位OS为73.9个月,而rct -手术组未达到中位OS (p = 0.909)。结论:对于晚期转移性大肠癌患者,采用多模式治疗策略联合全身化疗后淋巴结清扫(术前或不术前RCT)是可行的,其发病率低,肿瘤预后良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
10.80%
发文量
1698
审稿时长
2.8 months
期刊介绍: The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信